A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
| Study Name | |
| A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients with Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations | |
| ClinicalTrials.gov Identifier (if applicable) | |
| NCT05199584 | |
| Clinical Trial Category (check all that apply) | |
|
|
| Study Center | |
| Institution Name | |
| Endeavor Biomedicines | |
| State | |
| Country | |
| United States | |
| List additional Institutions (include address, phone number, and website) | |
| Sites are located all across the United States, with the ability to open additional locations closer to a patient’s home. | |
| Study Contacts | |
| Principal Investigator | |
| Endeavor Clinical Trials | |
| P.I. Phone | |
| (858) 727-3199 | |
| P.I. Email | |
| ebmclinical@ |
|
| Study Coordinator | |
| Endeavor Clinical Trials | |
| Study Coordinator Phone | |
| (858) 727-3199 | |
| Study Coordinator Email | |
| ebmclinical@ |
|
| OVERVIEW – in layman’s terms (150 words max) | |
| The study drug, ENV-101, acts on a protein in the body that is thought to be involved with the growth of these abnormal cells caused by a mutation of a gene, PTCH1. By blocking this process, ENV-101 may slow the progress of the disease or you may have a partial or complete response. |
|
| More Information | |
| Enrollment | |
| Ongoing | |
| Study Start Date | |
| 12/01/2021 | |
| Estimated Completion Date | |
| 5/31/2024 | |